Meiragtx Holdings Plc(MGTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MGTX Meiragtx Holdings Plc

交易中 05-07 13:30:18 EDT

9.54

-0.36

-3.64%

最高9.98	最低9.48	成交量16.35万
今开9.90	昨收9.90	日振幅5.05%
总市值8.83亿	流通市值5.10亿	总股本9,256万
成交额157.86万	换手率0.31%	流通股本5,345万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MGTX","market":"US","secType":"STK","nameCN":"Meiragtx Holdings Plc","latestPrice":9.54,"timestamp":1778175009519,"preClose":9.9,"halted":0,"volume":163462,"delay":0,"changeRate":-0.03636363636363649,"floatShares":53448500,"shares":92557200,"eps":-1.419877,"marketStatus":"交易中","change":-0.36,"latestTime":"05-07 13:30:18 EDT","open":9.9,"high":9.98,"low":9.48,"amount":1578579.7504230002,"amplitude":0.050505,"askPrice":9.53,"askSize":59,"bidPrice":9.49,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.419877,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1778184000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1528430400000,"exchange":"NASDAQ","adjPreClose":9.9,"preHourTrading":{"tag":"盘前","latestPrice":10.29,"preClose":9.9,"latestTime":"06:54 EDT","volume":8,"amount":82.262496,"timestamp":1778151281844,"change":0.39,"changeRate":0.039394,"amplitude":0.161869},"postHourTrading":{"tag":"盘后","latestPrice":9.9,"preClose":9.9,"latestTime":"16:10 EDT","volume":7317,"amount":72436.4,"timestamp":1778098243097,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.511993,"impliedVol":1.0132,"impliedVolPercentile":0.5418},"requestUrl":"/m/hq/s/MGTX/tweets","defaultTab":"tweets","newsList":[{"id":"1126177328","title":"强生与JJDc达成协议 MeiraGTx股票锁定期延长12个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1126177328","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126177328?lang=zh_cn&edition=full","pubTime":"2026-04-16 19:28","pubTimestamp":1776338880,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会最新披露的文件显示，强生公司及其子公司JJDc已与基因疗法公司MeiraGTx Holdings Plc达成重要协议。双方约定在交易完成后的12个月内，对持有的MeiraGTx股票实施锁定期限制。\n这一锁定安排意味着相关方在此期间不得出售或转让其持有的MeiraGTx股份。该举措通常被视为对公司长期发展前景的信心表现，有助于维护股价稳定和市场信心。\n作为基因治疗领域的知名企业，MeiraGTx专注于开发针对严重疾病的新型疗法。此次锁定期协议的达成，标志着合作双方战略伙伴关系的进一步深化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1585245621.USD","LU1894683264.USD","LU1778281490.HKD","LU2750360641.GBP","IE0001KFT4U8.USD","BK4581","LU1280957306.USD","SG9999002232.USD","IE00BVYPNW00.USD","LU0426412945.USD","IE0009355771.USD","BK4568","LU1032955483.USD","LU0289739699.SGD","IE0000B7K699.USD","BK4007","IE00B19Z3581.USD","IE000WAW04H5.SGD","LU1674673691.USD","LU1196500208.SGD","LU2133065610.SGD","LU1043141123.HKD","LU1732799900.SGD","BK4532","IE00B42XCP33.USD","LU0203347892.USD","LU1496350502.SGD","LU2129689514.USD","LU2430703095.HKD","LU0689626769.HKD","IE0034235303.USD","IE00BGHQF631.EUR","LU0432979614.USD","IE00BLSP4452.SGD","LU0792757196.USD","BK4534","LU0122379950.USD","LU1914381329.SGD","MGTX","LU1221951046.USD","LU2602419157.SGD","LU1506573853.SGD","LU1121112475.USD","BK4139","IE00BBT3K403.USD","LU1066053197.SGD","IE00B1BXHZ80.USD","LU1894683348.USD","IE00BDGV0183.EUR","LU0426417589.USD","IE0002270589.USD","BK4533","IE00BKVL7J92.USD","LU0345770308.USD","IE00B7SZLL34.SGD","BK4559","LU1043141396.HKD","BK4592","LU1221951129.SGD","LU1023059063.AUD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU1267930813.SGD","LU1066051811.HKD","LU1244550577.SGD","SGXZ57979304.SGD","IE000BZT7R73.USD","LU2129689431.USD","LU0640476718.USD","LU0098860793.USD","IE00B3T34201.USD","LU0124676726.USD","IE00BSNM7G36.USD","LU1929549753.HKD","SG9999001176.USD","IE00B19Z3B42.SGD","LU0985320562.USD","LU2347655156.SGD","IE00B3PB1722.GBP","LU0070217475.USD","LU0882574055.USD","LU1057294990.SGD","IE000F7OJYX1.SGD","LU0912757837.SGD","IE000SO60NU8.SGD","LU1162221912.USD","LU1935042991.SGD","LU2089984988.USD","LU0889566641.SGD","BK4588","LU1718418525.SGD","IE0002141913.USD","LU2592432038.USD","LU1066051498.USD","LU1244550494.USD","IE00BZ1G4Q59.USD","LU0203345920.USD","LU0787776722.HKD","LU2471134952.CNY","BK4550","IE000M9KFDE8.USD","LU0345769631.USD","LU0234570918.USD","IE00BFTCPJ56.SGD","LU0795875086.SGD","IE00BFXG1179.USD","LU2471134523.USD","IE000MB6IJN5.SGD","IE00BLSP4239.USD","LU1244550221.USD","LU0466842654.USD","LU1674673428.USD","LU2468319806.SGD","LU2471134879.HKD","LU2750360997.AUD","LU0345769128.USD","JNJ","LU2430703178.SGD","IE00B4R5TH58.HKD","LU2430703251.USD","LU1074936037.SGD","IE00BN8TJ469.HKD","BK4504","SG9999001176.SGD","LU2505996681.GBP","SG9999013999.USD","LU0994945656.USD","BK4585","SG9999001440.SGD","LU0345770993.USD","LU1059921491.USD","LU0058720904.USD","LU0795875169.SGD","LU0234572021.USD","LU1983299246.USD","LU2129689605.HKD","LU1066051225.USD","SG9999002224.SGD","LU2505996509.AUD","LU1732800096.USD","LU1032466523.USD","LU0114720955.EUR","LU2471134796.USD","LU0683600562.USD","LU2112291526.USD","IE00BVYPNV92.GBP","LU1430594728.SGD","LU0320765646.SGD","LU1261432733.SGD","IE00BJT1NW94.SGD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146946391","title":"MeiraGTx Holdings Plc与强生达成协议：自2029年7月1日起支付全球Rpgr销售额中位数百分比特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1146946391","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146946391?lang=zh_cn&edition=full","pubTime":"2026-04-16 19:24","pubTimestamp":1776338686,"startTime":"0","endTime":"0","summary":"根据最新提交的美国证券交易委员会文件披露，生物技术公司MeiraGTx Holdings Plc已与强生旗下杨森制药达成特许权使用费协议。该协议约定，自2029年7月1日起，MeiraGTx将就其基因疗法Rpgr的全球销售额向杨森支付中位数百分比范围的特许权使用费。特许权使用费的具体比例属于商业机密，但文件明确显示其处于\"中位数百分比\"区间，这通常意味着费率在15%左右浮动。该文件的披露为投资者提供了明确的前瞻性指引，有助于市场对MeiraGTx未来收入结构形成更清晰的预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188483589","title":"MeiraGTx与杨森协议包含5000万美元或有付款 基于RPGR产品里程碑达成","url":"https://stock-news.laohu8.com/highlight/detail?id=1188483589","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188483589?lang=zh_cn&edition=full","pubTime":"2026-04-16 19:24","pubTimestamp":1776338683,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会最新文件披露，生物制药公司MeiraGTx Holdings Plc与强生旗下杨森公司达成的XLPR合作协议中，包含一项价值5000万美元的或有付款条款。\n该笔款项的支付将完全取决于RPGR基因治疗产品能否实现预设的研发里程碑。协议细节显示，这笔或有资金将在特定临床开发节点触发支付机制，体现出合作方对创新疗法商业价值的共同期待。\n此次披露的财务安排进一步印证了双方在眼科基因治疗领域的深度绑定。里程碑付款作为生物科技领域常见的合作模式，既降低了药企前期投入风险，又为研发企业提供了明确的价值实现路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182348159","title":"MeiraGTx Holdings Plc将向强生支付2500万美元首付款、里程碑款项及两位数高额特许权使用费以获取Bota-Vec权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1182348159","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182348159?lang=zh_cn&edition=full","pubTime":"2026-04-16 19:11","pubTimestamp":1776337896,"startTime":"0","endTime":"0","summary":"生物技术公司MeiraGTx Holdings Plc与医疗保健巨头强生达成一项关于基因疗法Bota-Vec的授权协议。根据协议条款，MeiraGTx将向强生支付包括2500万美元首付款、后续里程碑款项以及高达两位数百分比的特许权使用费在内的多重财务对价。高额的特许权使用费条款凸显了该疗法在商业化后的潜在市场价值。通过获得Bota-Vec的权益，MeiraGTx有望进一步拓展其基因治疗产品管线。而对于强生而言，此次授权交易则体现了其通过外部合作优化研发资产组合的战略方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875086.SGD","LU1221951046.USD","LU0787776722.HKD","LU1066051225.USD","BK4581","IE00BFTCPJ56.SGD","LU2505996509.AUD","LU0432979614.USD","LU1061106388.HKD","LU2129689431.USD","LU1674673691.USD","LU1914381329.SGD","LU1935042991.SGD","LU1496350502.SGD","LU0070217475.USD","IE00BLSP4452.SGD","BK4532","LU0345770308.USD","LU2602419157.SGD","LU1074936037.SGD","LU0058720904.USD","LU0114720955.EUR","IE00B1BXHZ80.USD","IE00BBT3K403.USD","LU0689626769.HKD","LU0683600562.USD","LU2112291526.USD","LU1732800096.USD","IE000MB6IJN5.SGD","LU1043141123.HKD","LU2471134796.USD","IE00BVYPNV92.GBP","LU1929549753.HKD","SG9999001176.USD","IE00BLSP4239.USD","LU2471134523.USD","LU1732799900.SGD","LU1778281490.HKD","IE0000B7K699.USD","IE00B4R5TH58.HKD","LU0320765646.SGD","LU0640476718.USD","LU0426417589.USD","SG9999002224.SGD","LU0882574055.USD","JNJ","LU0124676726.USD","LU2430703178.SGD","IE0034235303.USD","LU2750360997.AUD","LU2089984988.USD","LU0203347892.USD","IE0002270589.USD","LU1261432733.SGD","IE000M9KFDE8.USD","BK4559","IE0001KFT4U8.USD","BK4007","SG9999001440.SGD","LU1244550494.USD","LU1023059063.AUD","LU0345770993.USD","LU1674673428.USD","LU2129689605.HKD","BK4588","MGTX","SG9999013999.USD","BK4585","LU0985320562.USD","LU0466842654.USD","BK4568","IE00BVYPNW00.USD","LU0122379950.USD","LU1244550221.USD","LU1032466523.USD","IE00B3T34201.USD","LU1894683264.USD","BK4139","LU1066051811.HKD","IE00B3PB1722.GBP","LU0234572021.USD","LU1718418525.SGD","LU0345769631.USD","LU2471134952.CNY","IE00B19Z3581.USD","LU2129689514.USD","SG9999002232.USD","IE00B7SZLL34.SGD","LU2430703095.HKD","IE0009355771.USD","LU1057294990.SGD","LU1506573853.SGD","IE000SO60NU8.SGD","LU1983299246.USD","IE00BFXG1179.USD","LU1430594728.SGD","LU0912757837.SGD","LU2133065610.SGD","IE00BJT1NW94.SGD","LU1032955483.USD","LU1244550577.SGD","LU0234570918.USD","IE000F7OJYX1.SGD","LU1267930813.SGD","LU2750360641.GBP","SG9999001176.SGD","LU0889566641.SGD","LU1585245621.USD","LU2430703251.USD","LU1221951129.SGD","IE00BKVL7J92.USD","LU1162221912.USD","LU2592432038.USD","LU0795875169.SGD","LU1043141396.HKD","IE00B2B36J28.USD","LU2505996681.GBP","IE00B19Z3B42.SGD","LU1066053197.SGD","BK4592","BK4550","IE00BGHQF631.EUR","LU0426412945.USD","IE00BSNM7G36.USD","IE00BN8TJ469.HKD","IE00B42XCP33.USD","IE00BZ1G4Q59.USD","LU0345769128.USD","LU0994945656.USD","LU1894683348.USD","LU2347655156.SGD","IE0002141913.USD","LU2468319806.SGD","LU0098860793.USD","LU0792757196.USD","LU0203345920.USD","LU1066051498.USD","BK4533","LU0289739699.SGD","SGXZ57979304.SGD","LU1059921491.USD","LU1280957306.USD","IE00BJJMRZ35.SGD","IE000WAW04H5.SGD","LU2471134879.HKD","LU1121112475.USD","LU1196500208.SGD","IE000BZT7R73.USD","IE00BDGV0183.EUR","BK4534","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164681875","title":"MeiraGTx宣布收购用于治疗X连锁视网膜色素变性疗法Bota-Vec","url":"https://stock-news.laohu8.com/highlight/detail?id=1164681875","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164681875?lang=zh_cn&edition=full","pubTime":"2026-04-16 19:11","pubTimestamp":1776337892,"startTime":"0","endTime":"0","summary":"基因治疗公司MeiraGTx近日正式完成对Botaretigene Sparoparvovec（简称Bota-Vec）疗法的收购，该疗法主要针对X连锁视网膜色素变性（XLRP）的治疗研发。此次收购标志着MeiraGTx在眼科基因治疗领域的重要战略布局。\nBota-Vec作为针对XLRP的潜在基因治疗手段，有望为患有该罕见遗传性视网膜疾病的患者提供新的治疗选择。X连锁视网膜色素变性会导致进行性视力丧失，目前尚无有效治疗方法。\n通过此次收购，MeiraGTx将进一步巩固其在视网膜疾病基因治疗研发领域的领先地位。公司表示将加速推进Bota-Vec的临床开发进程，尽早为患者带来创新治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164676419","title":"MeiraGTx公布AAV-hAQP1治疗2/3级晚期放射性口干症一期Aquax临床研究三年积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1164676419","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164676419?lang=zh_cn&edition=full","pubTime":"2026-04-16 19:01","pubTimestamp":1776337271,"startTime":"0","endTime":"0","summary":"生物技术公司MeiraGTx Holdings Plc近日宣布，其针对2/3级晚期放射性口干症开发的基因疗法AAV-hAQP1，在一期Aquax临床研究中展现出长达三年的持续积极疗效。该研究数据证实了该疗法在改善患者唾液分泌功能方面的持久性与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609302841","title":"Meiragtx Holdings Plc盘中异动 大幅跳水5.47%报7.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609302841","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609302841?lang=zh_cn&edition=full","pubTime":"2026-02-05 01:39","pubTimestamp":1770226783,"startTime":"0","endTime":"0","summary":"北京时间2026年02月05日01时39分，Meiragtx Holdings Plc股票出现波动，股价急速下跌5.47%。截至发稿，该股报7.60美元/股，成交量12.3179万股，换手率0.15%，振幅5.22%。Meiragtx Holdings Plc股票所在的生物技术行业中，整体涨幅为0.09%。Meiragtx Holdings Plc公司简介：MeiraGTx Holdings PLC 是一家临床阶段的基因治疗公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205013943a6d3b2e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205013943a6d3b2e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176425366","title":"MeiraGTx Holdings Plc与Perceptive生命科学主基金签订股份购买协议 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1176425366","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176425366?lang=zh_cn&edition=full","pubTime":"2026-01-02 21:06","pubTimestamp":1767359188,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新文件显示，MeiraGTx Holdings Plc已与Perceptive生命科学主基金正式签署股份购买协议。该协议标志着双方在资本层面的重要合作迈出实质性步伐。\n此次股份购买协议的签订，预计将为MeiraGTx Holdings Plc带来新的资金支持，助力其推进基因治疗领域的研发进程。作为一家专注于开发变革性基因疗法的生物技术公司，MeiraGTx通过此次与专业医疗健康投资机构的合作，有望进一步巩固其在行业内的竞争优势。\n协议具体条款及交易细节已在SEC备案文件中完整披露。市场关注此次股权交易将对公司未来发展产生的战略影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175123367","title":"MeiraGTx第三季度每股收益为-0.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1175123367","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175123367?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:43","pubTimestamp":1763574220,"startTime":"0","endTime":"0","summary":"11月13日 - MeiraGTx第三季度收入为41万美元，低于IBES预测的771万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582587009","title":"合作基因治疗项目 MeiraGTx(MGTX)涨11% 礼来(LLY)涨近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582587009","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582587009?lang=zh_cn&edition=full","pubTime":"2025-11-10 23:01","pubTimestamp":1762786884,"startTime":"0","endTime":"0","summary":"金吾财讯 | 礼来(LLY)股价冲高，截至发稿，涨5.84%，报978美元。MeiraGTx(MGTX)升11.45%，报9.44美元。根据协议，总部位于纽约的生物技术公司MeiraGTx将授予礼来其AAV-AIPL1基因治疗项目的全球独家权利，以开发针对一种遗传性眼病的药物。该病为Leber先天性黑蒙4型(LCA4)，由芳基烃相互作用蛋白样1(AIPL1)基因缺陷所致，MeiraGTx已将其认定为最严重的遗传性视网膜病变之一。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/NTE3MzYyMzA2NDI2MjU=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NTE3MzYyMzA2NDI2MjU=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9502e9704f0d2a25f1fd7559c85b01d7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"294301","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","LU0109394709.USD","LU0823434740.USD","SGXZ57979304.SGD","LU2237438978.USD","LU2112291526.USD","LU2750360997.AUD","LU0432979614.USD","LU0943347566.SGD","LU2237443465.HKD","LU0096364046.USD","LU2456880835.USD","LU0353189763.USD","LU0889565916.HKD","LU0094547139.USD","LU2471134879.HKD","LU2471134796.USD","LU2750360641.GBP","MGTX","BK4588","LU1064131342.USD","LU1551013342.USD","LU0061475181.USD","LU0708995401.HKD","LU0354030511.USD","LU0234572021.USD","SGXZ81514606.USD","LU1232071149.USD","LU0320765059.SGD","BK4599","LU0385154629.USD","LU2471134952.CNY","LU0456855351.SGD","LU0786609619.USD","LU2360106947.USD","LU2602419157.SGD","LU2324357040.USD","LU2552382132.HKD","LU0882574055.USD","LU2236285917.USD","IE00BJLML261.HKD","LU2471134523.USD","LU0823434583.USD","LU2552382058.USD","LU0820561818.USD","LU0316494557.USD","LU2552382215.SGD","IE00BFTCPJ56.SGD","LU1069344957.HKD","LU1988902786.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162470969","title":"MeiraGTx Holdings股价因与Eli Lilly合作治疗罕见眼病上涨11.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162470969","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162470969?lang=zh_cn&edition=full","pubTime":"2025-11-10 21:15","pubTimestamp":1762780556,"startTime":"0","endTime":"0","summary":"MeiraGTx Holdings股价因与Eli Lilly合作治疗罕见眼病上涨11.5%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9502e9704f0d2a25f1fd7559c85b01d7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179288922","title":"MeiraGTx与礼来公司达成战略合作开发眼科基因药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1179288922","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179288922?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:01","pubTimestamp":1762776071,"startTime":"0","endTime":"0","summary":"MeiraGTx与礼来公司达成战略合作，旨在开发和商业化眼科领域的基因药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9502e9704f0d2a25f1fd7559c85b01d7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518327139","title":"Meiragtx Holdings Plc盘中异动 早盘股价大跌5.41%报6.04美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518327139","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518327139?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:33","pubTimestamp":1741617231,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时33分，Meiragtx Holdings Plc股票出现异动，股价急速下挫5.41%。截至发稿，该股报6.04美元/股，成交量3.4789万股，换手率0.04%，振幅4.47%。Meiragtx Holdings Plc股票所在的生物技术行业中，整体涨幅为0.02%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3472.35%、736.73%、546.53%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.，振幅分别为41.36%、40.33%、40.24%。Meiragtx Holdings Plc公司简介：MeiraGTx Holdings PLC 是一家临床阶段的基因治疗公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022335198a2ac83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022335198a2ac83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516786670","title":"Meiragtx Holdings Plc盘中异动 急速下挫5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516786670","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516786670?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:35","pubTimestamp":1741098901,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时35分，Meiragtx Holdings Plc股票出现异动，股价快速下挫5.85%。截至发稿，该股报6.10美元/股，成交量2.1485万股，换手率0.03%，振幅2.57%。Meiragtx Holdings Plc股票所在的生物技术行业中，整体涨幅为0.11%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Protagenic Therapeutics, Inc.、Capricor Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1075.00%、1069.41%、423.76%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Adma Biologics Inc、Ibio, Inc.，振幅分别为23.30%、12.57%、12.01%。Meiragtx Holdings Plc公司简介：MeiraGTx Holdings PLC 是一家临床阶段的基因治疗公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223501989bacfa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223501989bacfa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516655180","title":"Meiragtx Holdings Plc盘中异动 临近午盘快速跳水5.29%报6.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516655180","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516655180?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:37","pubTimestamp":1741019850,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日00时37分，Meiragtx Holdings Plc股票出现波动，股价大幅下跌5.29%。截至发稿，该股报6.75美元/股，成交量6.1428万股，换手率0.08%，振幅6.31%。Meiragtx Holdings Plc股票所在的生物技术行业中，整体跌幅为0.30%。其相关个股中，Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为3894.91%、173.23%、141.72%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、90.70%、70.53%。Meiragtx Holdings Plc公司简介：MeiraGTx Holdings PLC 是一家临床阶段的基因治疗公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304003730a25d6649&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304003730a25d6649&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513177336","title":"Meiragtx Holdings Plc盘中异动 大幅下跌5.25%报6.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513177336","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513177336?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:30","pubTimestamp":1740411033,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时30分，Meiragtx Holdings Plc股票出现异动，股价快速跳水5.25%。截至发稿，该股报6.92美元/股，成交量20.3815万股，换手率0.26%，振幅7.53%。Meiragtx Holdings Plc股票所在的生物技术行业中，整体涨幅为0.28%。其相关个股中，Pepgen Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为204.41%、85.68%、27.82%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ，振幅分别为137.23%、55.69%、53.34%。Meiragtx Holdings Plc公司简介：MeiraGTx Holdings PLC 是一家临床阶段的基因治疗公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224233033abdb1bef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224233033abdb1bef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513966662","title":"Meiragtx Holdings Plc盘中异动 早盘大幅拉升7.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513966662","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513966662?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:30","pubTimestamp":1740148223,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时30分，Meiragtx Holdings Plc股票出现异动，股价急速拉升7.72%。截至发稿，该股报7.36美元/股，成交量2.8589万股，换手率0.04%，振幅2.01%。Meiragtx Holdings Plc股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Osr Holdings, Inc.、Estrella Immunopharma, Inc.、Editas Medicine, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、蓝鸟生物较为活跃，换手率分别为68.30%、58.99%、16.57%，振幅较大的相关个股有Editas Medicine, Inc.、Kairos Pharma, Ltd.、Q32 Bio Inc.，振幅分别为3.40%、3.01%、2.88%。Meiragtx Holdings Plc公司简介：MeiraGTx Holdings PLC 是一家临床阶段的基因治疗公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223023a24eafc6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223023a24eafc6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512316674","title":"Meiragtx Holdings Plc盘中异动 早盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512316674","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512316674?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:52","pubTimestamp":1739890377,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时52分，Meiragtx Holdings Plc股票出现波动，股价急速上涨5.00%。截至发稿，该股报7.04美元/股，成交量5.4531万股，换手率0.07%，振幅4.10%。Meiragtx Holdings Plc股票所在的生物技术行业中，整体涨幅为0.94%。其相关个股中，Revolution Medicines Inc C/Wts 17/12/2026 、Allogene Therapeutics, Inc.、Pulmatrix, Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Glycomimetics, Inc.较为活跃，换手率分别为320.14%、96.57%、54.70%，振幅较大的相关个股有Cosciens Biopharma Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Jasper Therapeutics Inc C/Wts 24/09/2026 ，振幅分别为98.91%、41.79%、34.04%。Meiragtx Holdings Plc公司简介：MeiraGTx Holdings PLC 是一家临床阶段的基因治疗公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021822525796279bc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021822525796279bc9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510038034","title":"Meiragtx Holdings Plc盘中异动 股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510038034","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510038034?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:44","pubTimestamp":1739285055,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时44分，Meiragtx Holdings Plc股票出现异动，股价大幅下挫5.10%。截至发稿，该股报6.33美元/股，成交量2.22万股，换手率0.03%，振幅3.00%。Meiragtx Holdings Plc股票所在的生物技术行业中，整体跌幅为1.27%。其相关个股中，Dominari Holdings Inc.、Ocean Biomedical, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2325.14%、611.45%、251.11%，振幅较大的相关个股有Dominari Holdings Inc.、Ocean Biomedical, Inc.、In8Bio, Inc.，振幅分别为34.58%、33.04%、33.02%。Meiragtx Holdings Plc公司简介：MeiraGTx Holdings PLC 是一家临床阶段的基因治疗公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211224415961f4a3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211224415961f4a3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509358962","title":"Meiragtx Holdings Plc盘中异动 大幅拉升5.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509358962","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509358962?lang=zh_cn&edition=full","pubTime":"2025-02-05 23:58","pubTimestamp":1738771082,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日23时58分，Meiragtx Holdings Plc股票出现波动，股价急速上涨5.54%。截至发稿，该股报6.67美元/股，成交量5.9214万股，换手率0.08%，振幅3.64%。Meiragtx Holdings Plc股票所在的生物技术行业中，整体涨幅为1.26%。其相关个股中，Transcode Therapeutics, Inc.、Oragenics Inc.、Pasithea Therapeutics Corp.涨幅较大，Pasithea Therapeutics Corp.、Transcode Therapeutics, Inc.、Oragenics Inc.较为活跃，换手率分别为4194.92%、1370.21%、1268.00%，振幅较大的相关个股有Transcode Therapeutics, Inc.、Oragenics Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028，振幅分别为94.64%、59.80%、54.05%。Meiragtx Holdings Plc公司简介：MeiraGTx Holdings PLC 是一家临床阶段的基因治疗公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205235803961918ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205235803961918ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MGTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.meiragtx.com","stockEarnings":[{"period":"1week","weight":0.1061},{"period":"1month","weight":0.0399},{"period":"3month","weight":0.375},{"period":"6month","weight":0.1688},{"period":"1year","weight":0.6865},{"period":"ytd","weight":0.2453}],"compareEarnings":[{"period":"1week","weight":0.0313},{"period":"1month","weight":0.1137},{"period":"3month","weight":0.083},{"period":"6month","weight":0.0937},{"period":"1year","weight":0.3132},{"period":"ytd","weight":0.0761}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"MeiraGTx Holdings plc于2018年5月1日根据开曼群岛法律成立。该公司是一家垂直整合的临床阶段基因药物公司，拥有广泛的晚期临床项目，包括放射性口干症、帕金森病和AIPL1相关的视网膜营养不良。该公司的临床项目使用有针对性的局部小剂量遗传药物来治疗遗传性疾病和更常见的严重未满足需求的疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.012037},{"month":2,"riseRate":0.5,"avgChangeRate":0.0333},{"month":3,"riseRate":0.25,"avgChangeRate":-0.052743},{"month":4,"riseRate":0.75,"avgChangeRate":-0.013966},{"month":5,"riseRate":0.625,"avgChangeRate":0.003323},{"month":6,"riseRate":0.428571,"avgChangeRate":0.028652},{"month":7,"riseRate":0.625,"avgChangeRate":0.025554},{"month":8,"riseRate":0.375,"avgChangeRate":-0.045501},{"month":9,"riseRate":0.75,"avgChangeRate":-0.003363},{"month":10,"riseRate":0.375,"avgChangeRate":0.087707},{"month":11,"riseRate":0.625,"avgChangeRate":0.051284},{"month":12,"riseRate":0.625,"avgChangeRate":0.053515}],"exchange":"NASDAQ","name":"Meiragtx Holdings Plc","nameEN":"Meiragtx Holdings Plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Meiragtx Holdings Plc(MGTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Meiragtx Holdings Plc(MGTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Meiragtx Holdings Plc,MGTX,Meiragtx Holdings Plc股票,Meiragtx Holdings Plc股票老虎,Meiragtx Holdings Plc股票老虎国际,Meiragtx Holdings Plc行情,Meiragtx Holdings Plc股票行情,Meiragtx Holdings Plc股价,Meiragtx Holdings Plc股市,Meiragtx Holdings Plc股票价格,Meiragtx Holdings Plc股票交易,Meiragtx Holdings Plc股票购买,Meiragtx Holdings Plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Meiragtx Holdings Plc(MGTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Meiragtx Holdings Plc(MGTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}